The global arrhythmia monitoring devices market size is expected to reach USD 12.03 billion in 2030 with a CAGR of 7.4% during the forecast period. Continuous R&D activities in the field of cardiac monitoring are leading to technological expansion. This, in turn, is positively influencing the growth of the arrhythmia monitoring devices market. Wearable diagnostic patch by iRhythm Technologies, Inc., Zio, has led to symptomatic arrhythmia monitoring, which is superior in comparison to conventional Holter monitors.
Big pharma and medical device companies are heavily investing in R&D to perform a detailed mapping of cardiac arrhythmia. In February 2018, Medtronic received FDA clearance for the first non-invasive cardiac mapping system, CardioInsight. It includes wearable 252-electrode sensor vest that creates 3D electroanatomic maps of heart by combining data from a cardiac computed tomography scan with ECG signals collected from the chest region.
In addition to these technologies, emergence and advancements in mobile cardiac telemetry are leading to further progress of the overall market. In October 2017, Abbott received FDA clearance for Confirm Rx, a smartphone-compatible implantable cardiac monitor indicated for arrhythmia diagnosis. Boston Scientific announced its FDA approval for Resonate, a line of cardiac resynchronization therapy defibrillator and cardioverter defibrillator systems for the cardiac management.
This product will be delivered within 2 business days.
Big pharma and medical device companies are heavily investing in R&D to perform a detailed mapping of cardiac arrhythmia. In February 2018, Medtronic received FDA clearance for the first non-invasive cardiac mapping system, CardioInsight. It includes wearable 252-electrode sensor vest that creates 3D electroanatomic maps of heart by combining data from a cardiac computed tomography scan with ECG signals collected from the chest region.
In addition to these technologies, emergence and advancements in mobile cardiac telemetry are leading to further progress of the overall market. In October 2017, Abbott received FDA clearance for Confirm Rx, a smartphone-compatible implantable cardiac monitor indicated for arrhythmia diagnosis. Boston Scientific announced its FDA approval for Resonate, a line of cardiac resynchronization therapy defibrillator and cardioverter defibrillator systems for the cardiac management.
Arrhythmia Monitoring Devices Market Report Highlights
- Holter monitors dominated the market in terms of revenue in 2023. On the other hand, mobile cardiac telemetry is expected to witness the fastest growth rate during the forecast period
- Atrial fibrillation dominated the market in terms of revenue in 2023. The growth in the number of untreated cases of arrhythmias are leading to increasing need for advanced cardiac monitoring devices
- Heightened adoption of sophisticated technologies has led to the expansion of the market. Kardia Mobile by AliveCor captures ECG in 30 seconds projecting the heart rhythm for conditions such as atrial fibrillation
- The hospitals and clinics segment held the largest share in the market in 2023. On the other hand, diagnostic centers are likely to experience the fastest growth over the forecast period
The leading players in the Arrhythmia Monitoring Devices market include:
- Abbott
- ACS Diagnostics
- GE HeathCare
- Biotronik
- iRhythm Technologies, Inc.
- Medtronic
- Koninklijke Philips N.V.
- FUKUDA DENSHI
- Spacelabs Healthcare
- AliveCor, Inc.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Arrhythmia Monitoring Market Variables, Trends, & Scope
Chapter 4. Arrhythmia Monitoring Market: Type Estimates & Trend Analysis
Chapter 5. Arrhythmia Monitoring Market: Application Estimates & Trend Analysis
Chapter 6. Arrhythmia Monitoring Market: End Use Estimates & Trend Analysis
Chapter 7. Arrhythmia Monitoring Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
The leading players in the Arrhythmia Monitoring Devices market include:- Abbott
- ACS Diagnostics
- GE HeathCare
- Biotronik
- iRhythm Technologies, Inc.
- Medtronic
- Koninklijke Philips N.V.
- FUKUDA DENSHI
- Spacelabs Healthcare
- AliveCor, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 7.34 Billion |
| Forecasted Market Value ( USD | $ 12.03 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
